US FDA approves new anti-Alzheimer's drug

US FDA approves new anti-Alzheimer's drug

• By Staff Writer

The US Food and Drug Administration (FDA) has approved a new drug which aims to slow cognitive decline in patients of Alzheimer's disease. The new treatment is called Leqembi or lecanemab. It was approved in an accelerated process. The approval comes after another anti-Alzheimer's drug, Aduhelm, was approved but was criticised by a US congressional investigation team for alleged "irregularities".